New combo shows promise in holding back prostate cancer
Disease control
Completed
This study tested a combination of two drugs, abiraterone acetate and prednisone, in 131 men with advanced prostate cancer that had not yet shown up on scans. The goal was to see if the treatment could lower a key cancer marker (PSA) and delay the time until the cancer visibly gr…
Phase: PHASE2 • Sponsor: Janssen Biotech, Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC